Skip to main navigation
Skip to search
Skip to main content
University of Kentucky Home
LOGIN & Help
Home
Research units
Researchers
Projects & Grants
Research Output
Facilities & Equipment
Honors & Awards
Activities
Search by expertise, name or affiliation
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and D
Monohan, Gregory
(PI)
Markey Cancer Center / Cancer Research Priority Initiative
Overview
Grants and Contracts Details
Status
Finished
Effective start/end date
3/15/22
→
1/29/24
Funding
Janssen Research and Development LLC:
$27,139.00
View all
View less